Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lung cancer patients

AstraZeneca AZ

After MYSTIC setback, FDA gives some comfort to AZ

Awards its PD-L1 inhibitor Imfinzi breakthrough status in locally-advanced NSCLC

AstraZeneca AZ

Shock for AZ as MYSTIC trial stumbles at first hurdle

Combination fails to improve progression-free survival for lung cancer patients

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

AstraZeneca AZ

Grünenthal buys Zomig rights as AZ slimming drive continues

Acquires global rights outside Japan to the migraine drug

- PMLiVE

AZ’s Lynparza shows PARP inhibitor potential in breast cancer

Findings were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

- PMLiVE

Recordati acquires AstraZeneca blood pressure brands

Italian pharma firm obtains Seloken and Logimax

AstraZeneca AZ

AZ buoyed by Imfinzi lung cancer trial

Phase III study shows PD-L1 inhibitor increased progression-free survival

- PMLiVE

Merck gains ground in lung cancer with first-line combo approval

Keytruda wins FDA backing for all first-line NSCLC patients

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

- PMLiVE

Unhappy times continue at OncoMed with more disappointing results

Lung cancer candidate tarextumab fails phase II trial

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links